IQ-13

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Fetal valproate exposure was associated with lower IQ at age 6 years compared to other AEDs, with adjusted IQ 7-13 points worse, in a dose-dependent manner.

Effect: adverse; adjusted IQ worse by 7-13 IQ points for valproate compared to other drugs

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7

Periconception folate use was associated with higher child IQ at age 6 years, with adjusted IQ 6 points higher in the folate group compared to those without periconception folate.

Effect: improvement; adjusted IQ 6 points higher for folate group (regression coefficient 5.7); CI: 95% CI, 1.7 to 9.7